Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > POC in humans has been acheived is that it

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on May 02, 2024 7:20pm

102 Views

Post# 36020649

RE:RE:RE:RE:RE:RE:RE:POC in humans has been acheived is that it

If I correctly recall Dr. Winer during a video presentation for Thera was definitely encouraged about TH1902 potential and mentioned one of his patients that had dropped out of the trial for personal reasons yet who’s cancer was amazingly not progressing, I believe he attributed that to some of the other benefits of TH1902, thinking he mentioned the patient was due soon for another follow exam at the time….Guess we will find out when the abstract is posted.

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks